Bnb Plus CORP. (BNBX) — SEC Filings

Q: What are the key financial highlights for Bnb Plus CORP.?

Key financial highlights for Bnb Plus CORP. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bnb Plus CORP.?

Key executives at Bnb Plus CORP. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bnb Plus CORP. stock?

Risk factors for Bnb Plus CORP. (BNBX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bnb Plus CORP.?

Forward-looking statements and predictions from Bnb Plus CORP. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bnb Plus CORP.. Recent 10-K filing on Dec 22, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Bnb Plus CORP. on SEC EDGAR

Overview

Bnb Plus CORP. (BNBX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 22, 2025: BNB PLUS CORP. (BNBX) pivoted to a digital asset treasury (DAT) strategy in October 2025, focusing on accumulating and generating yield from BNB, the native cryptocurrency of the Binance blockchain ecosystem. This strategic shift was initiated with a private placement offering that secured $26.8 mil

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 45 neutral, 1 mixed. The dominant filing sentiment for Bnb Plus CORP. is neutral.

Filing Type Overview

Bnb Plus CORP. (BNBX) has filed 2 10-K, 31 8-K, 2 S-1, 4 10-Q, 3 DEF 14A, 1 DEFA14A, 1 S-1/A, 2 SC 13G, 4 SC 13G/A with the SEC between Aug 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

BNBX Pivots to BNB-Centric Digital Asset Strategy, Secures $26.8M — 10-K · Dec 22, 2025 Risk: high
BNB PLUS CORP. (BNBX) pivoted to a digital asset treasury (DAT) strategy in October 2025, focusing on accumulating and generating yield from BNB, the native cry
8-K Filing — 8-K · Dec 15, 2025
8-K Filing — 8-K · Nov 17, 2025
Applied DNA Sciences Elects New Directors, Adjusts Executive Pay — 8-K · Nov 10, 2025 Risk: medium
Applied DNA Sciences, Inc. announced on November 6, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two ne
Applied DNA Sciences Files 8-K — 8-K · Nov 4, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on November 4, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhibit
BNBX Pivots to Crypto: $57.6M Raise Fuels Binance Coin Treasury Strategy — S-1 · Oct 30, 2025 Risk: high
Applied DNA Sciences, Inc. (BNBX) filed an S-1 on October 30, 2025, primarily to register the resale of up to 18,728,341 shares of common stock by selling stock
Applied DNA Sciences Files 8-K — 8-K · Oct 23, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on October 23, 2025, reporting events as of October 21, 2025. The filing primarily concerns financial statements and exh
Applied DNA Sciences Files 8-K on Exit Costs — 8-K · Oct 6, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on October 6, 2025, reporting on cost associated with exit or disposal activities as of September 30, 2025. The filing a
Applied DNA Sciences Files 8-K with Key Corporate Updates — 8-K · Oct 1, 2025 Risk: medium
Applied DNA Sciences Inc. entered into a material definitive agreement on September 29, 2025. The company also reported on unregistered sales of equity securiti
Applied DNA Sciences Files 8-K with Material Agreements and Officer Changes — 8-K · Sep 29, 2025 Risk: medium
On September 29, 2025, Applied DNA Sciences, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement,
APDN Plunges to $3.98M Loss Amid Strategic Restructuring — 10-Q · Aug 14, 2025 Risk: high
APPLIED DNA SCIENCES INC. (BNBX) reported a significant net loss of $3,984,109 for the three months ended June 30, 2025, a stark contrast to the net income of $
Applied DNA Sciences Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition, and including financial statements a
Applied DNA Sciences Sells Certainty Business — 8-K · Jul 7, 2025 Risk: medium
Applied DNA Sciences, Inc. announced on July 2, 2025, that it has entered into a definitive agreement to sell its Certainty business to an unaffiliated third pa
Applied DNA Sciences Files 8-K with Executive and Financial Updates — 8-K · Jun 30, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on June 30, 2025, reporting events as of June 27, 2025. The filing indicates items related to cost associated with exit
Applied DNA Sciences Files 8-K with Officer/Director Updates — 8-K · Jun 17, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on June 17, 2025, reporting events as of June 16, 2025. The filing indicates changes related to directors and officers,
Applied DNA Sciences Faces Delisting Concerns — 8-K · Jun 6, 2025 Risk: high
Applied DNA Sciences, Inc. filed an 8-K on June 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the da
Applied DNA Sciences Files 8-K with Bylaw Amendments — 8-K · May 29, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on May 29, 2025, reporting amendments to its Articles of Incorporation or Bylaws, a Regulation FD Disclosure, and Financ
Applied DNA Sciences Files 8-K on Shareholder Votes — 8-K · May 22, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on May 22, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corp
Applied DNA Sciences Files 10-Q for March 31, 2025 — 10-Q · May 15, 2025 Risk: medium
Applied DNA Sciences Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business opera
Applied DNA Sciences Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition, and including financial statements and
Applied DNA Sciences Files Proxy Statement for May 22 Meeting — DEF 14A · Apr 15, 2025 Risk: medium
Applied DNA Sciences Inc. filed its definitive proxy statement on April 15, 2025, for its annual meeting on May 22, 2025. The company, previously known as ProHe
Applied DNA Sciences Files 8-K — 8-K · Apr 8, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on April 8, 2025, reporting other events and financial statements and exhibits. The filing date indicates the report was
Applied DNA Sciences Files 8-K on Shareholder Nominations — 8-K · Apr 1, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on April 1, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for this repor
Applied DNA Sciences Files 8-K with Bylaw Amendments — 8-K · Mar 12, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on March 12, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and fina
Applied DNA Sciences Files 8-K on Shareholder Votes — 8-K · Feb 28, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on February 28, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain spec
Applied DNA Sciences Files 8-K on Shareholder Votes — 8-K · Feb 14, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on February 14, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain spec
Applied DNA Sciences Files 10-Q for Dec 31, 2024 — 10-Q · Feb 13, 2025 Risk: medium
Applied DNA Sciences Inc. filed its 10-Q for the period ending December 31, 2024. The company reported financial results and provided updates on its business op
Applied DNA Sciences Files 8-K on Financials — 8-K · Feb 13, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on February 13, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
Applied DNA Sciences Files Proxy Statement — DEFA14A · Feb 11, 2025 Risk: low
Applied DNA Sciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on February 11, 2025. This filing is related to the company's proxy materials, which are
Applied DNA Sciences Changes Certifying Accountant — 8-K · Jan 30, 2025 Risk: medium
Applied DNA Sciences, Inc. filed an 8-K on January 30, 2025, reporting a change in its certifying accountant. The company's previous independent registered publ
Applied DNA Sciences Files 8-K on Shareholder Votes — 8-K · Jan 23, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on January 23, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
Applied DNA Sciences Files 8-K — 8-K · Jan 13, 2025 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on January 13, 2025, reporting information under Regulation FD and including financial statements and exhibits. The comp
Applied DNA Sciences Files S-1/A Amendment — S-1/A · Jan 10, 2025 Risk: low
Applied DNA Sciences, Inc. filed an amendment (S-1/A) on January 10, 2025, to its registration statement. The company, formerly known as ProHealth Medical Techn
Applied DNA Sciences Files 2024 10-K — 10-K · Dec 17, 2024 Risk: medium
Applied DNA Sciences Inc. filed its 10-K for the fiscal year ending September 30, 2024. The company, headquartered in Stony Brook, NY, reported financial data f
Applied DNA Sciences Sells Certainty Business for $10M — 8-K · Dec 17, 2024 Risk: medium
Applied DNA Sciences, Inc. announced on December 17, 2024, that it has entered into a definitive agreement to sell its Certainty business to an unaffiliated thi
Applied DNA Sciences Files 2025 Proxy Statement — DEF 14A · Dec 10, 2024 Risk: low
Applied DNA Sciences Inc. is filing its definitive proxy statement for the 2025 annual meeting of stockholders, scheduled for January 23, 2025. The filing, subm
Applied DNA Sciences Files S-1 for Securities Offering — S-1 · Nov 19, 2024 Risk: medium
Applied DNA Sciences Inc. filed an S-1 registration statement on November 19, 2024, to register an unspecified number of securities. The company, incorporated i
SC 13G Filing — SC 13G · Nov 14, 2024
Applied DNA Sciences Faces Delisting Concerns — 8-K · Nov 13, 2024 Risk: high
Applied DNA Sciences, Inc. filed an 8-K on November 13, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The co
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Applied DNA Sciences Files 8-K with Bylaw Amendments — 8-K · Nov 7, 2024 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on November 7, 2024, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
Applied DNA Sciences Files 8-K: Material Agreement & Equity Sale — 8-K · Oct 31, 2024 Risk: medium
Applied DNA Sciences, Inc. entered into a Material Definitive Agreement on October 30, 2024, related to the unregistered sale of equity securities. The company
SC 13G Filing — SC 13G · Oct 2, 2024
Applied DNA Sciences Files 8-K on Security Holder Votes — 8-K · Sep 30, 2024 Risk: low
Applied DNA Sciences, Inc. filed an 8-K on September 30, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail the
Applied DNA Sciences Sells Certainty Business for $15M — 8-K · Sep 18, 2024 Risk: medium
Applied DNA Sciences, Inc. announced on September 17, 2024, that it has entered into a definitive agreement to sell its Certainty business to an unaffiliated th
Applied DNA Sciences Files Proxy Statement — DEF 14A · Aug 21, 2024 Risk: medium
Applied DNA Sciences Inc. filed a definitive proxy statement (DEF 14A) on August 21, 2024, for its fiscal year ending September 30, 2024. The filing concerns th
SC 13G/A Filing — SC 13G/A · Aug 19, 2024
SC 13G/A Filing — SC 13G/A · Aug 9, 2024
Applied DNA Sciences Files Q3 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
Applied DNA Sciences Inc. reported its financial results for the quarter ending June 30, 2024. The company's fiscal year ends on September 30th. The filing deta

Risk Profile

Risk Assessment: Of BNBX's 42 recent filings, 5 were flagged as high-risk, 21 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bnb Plus CORP.'s most recent 10-K filing (Dec 22, 2025):

Revenue: $0
Net Income: $0
EPS: $0
Debt-to-Equity: 0.0
Cash Position: $26.8M
Operating Margin: N/A
Total Assets: $26.8M
Total Debt: $0

Key Executives

Dr. Kenneth L. Miller
Mr. Robert L. B. Jr.
Dr. James A. Hayward
Ms. Melissa L. St. Clair
Clay Shorrock
Merrill M. Kraines
Todd Kornfeld
James A. Hayward, Ph.D., Sc.D.

Industry Context

The digital asset treasury (DAT) sector is rapidly evolving, driven by the increasing adoption of cryptocurrencies as alternative reserve assets. Companies in this space focus on yield generation through various DeFi protocols and blockchain ecosystem participation. The competitive landscape includes other digital asset managers and traditional financial institutions exploring crypto exposure. Key trends involve the development of more sophisticated yield-generating strategies and the increasing integration of blockchain technology into financial services.

Top Tags

corporate-governance (10) · financials (8) · filing (7) · governance (6) · shareholder-vote (5) · material-agreement (4) · financial-reporting (4) · proxy-statement (4) · Biotechnology (3) · 8-K (3)

Key Numbers

Gross proceeds from Private Placement: $26.8M — Initial funding for BNB Strategy in October 2025
Potential additional gross proceeds: $30.8M — From future warrant exercises, further funding the BNB Strategy
Aggregate market value of non-affiliate common stock: $10.5M — As of March 31, 2025, indicating a smaller market capitalization
Shares of common stock outstanding: 4,365,541 — As of December 15, 2025
Initial total supply of BNB tokens: 200M — Targeted to be reduced to 100 million through burn policy
Target total supply of BNB tokens: 100M — After burn policy implementation
BNB reportedly remaining to be burned: 37M — As of October 2025, to reach the 100 million target
Maximum theoretical transactions per second on BNB Chain: 2,000+ — Indicates high throughput capability
Approximate gas fees per transaction on BNB Chain: $0.01 — Facilitates wide user participation and micro-transactions
Launch of DAT strategy: October 2025 — Marks the company's strategic pivot
Gross proceeds received: $26.7M — From the initial closing of the Private Placement
Total potential gross proceeds: $57.6M — From the Private Placement including warrant exercises
Shares of Common Stock: 18,728,341 — Maximum shares registered for resale by selling stockholders
Offering price per share: $3.32 — For Common Shares and Pre-Funded Warrants in the Private Placement
Exercise price per share: $3.82 — For Series E Warrants, Placement Agent Warrants, Advisory Warrants, and Consultant Warrants

Related Companies

OBNB · APDN · BNB-USD · ADNA

Frequently Asked Questions

What are the latest SEC filings for Bnb Plus CORP. (BNBX)?

Bnb Plus CORP. has 50 recent SEC filings from Aug 2024 to Dec 2025, including 31 8-K, 4 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BNBX filings?

Across 50 filings, the sentiment breakdown is: 4 bearish, 45 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Bnb Plus CORP. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bnb Plus CORP. (BNBX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bnb Plus CORP.?

Key financial highlights from Bnb Plus CORP.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BNBX?

The investment thesis for BNBX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bnb Plus CORP.?

Key executives identified across Bnb Plus CORP.'s filings include Dr. Kenneth L. Miller, Mr. Robert L. B. Jr., Dr. James A. Hayward, Ms. Melissa L. St. Clair, Clay Shorrock and 3 others.

What are the main risk factors for Bnb Plus CORP. stock?

Of BNBX's 42 assessed filings, 5 were flagged high-risk, 21 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Bnb Plus CORP.?

Forward guidance and predictions for Bnb Plus CORP. are extracted from SEC filings as they are enriched.